Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) Henry Ji, Ph.D. Chief Executive Officer, President & Chairperson 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Na ...

At the same time, rotational strength in heavyweight stocks across sectors is providing support and helping the index hold its ground amid the ongoing consolidation phase.In today's trade, shares of Hyundai India, SBI, Zydus Life, said it is aiming for a capex of Rs 25,000 crore in the current fiscal year and will look to maintain the same annual spend till FY30. As per an investor presentation, 65 per cent of the capex is aimed at clean energy projects. Tata Power, which made a capital expenditure (capex ...

Core Insights - ADEL, a South Korea-based biotech company, has announced a partnership with French drugmaker Sanofi valued at $1.04 billion to develop and commercialize an experimental treatment for Alzheimer's disease [1] Company Summary - ADEL is focusing on the development of a new treatment for Alzheimer's disease, indicating a strategic move into a high-demand therapeutic area [1] - The partnership with Sanofi represents a significant financial commitment, highlighting the potential value of ADEL's research and development efforts in the biotech sector [1] Industry Summary - The collaboration between ADEL and Sanofi underscores the growing interest and investment in Alzheimer's disease treatments, reflecting the increasing urgency to address this global health challenge [1] - The $1.04 billion partnership may set a precedent for future collaborations in the biotech industry, particularly in the field of neurodegenerative diseases [1]

For more, let's bring in Amy Burroughs, the CEO of Turns Pharmaceuticals. Amy, great to have you with us. >> Thank you so much for having me back, Melissa.>> This was stunning for most investors, most analysts out there in terms of of the data. Three times better approximately than the standard of care right now. Can you can you sort of speak to what this means for patients and and how soon this drug can actually reach market.>> Yeah, absolutely. So chronic myo leukemia is a disease which is a chronic condi ...

Final trade time, Tim. [music] >> Yeah, J&J. I think you've got consumer products. You got MedTech and you've got oncology.>> Karen. >> Yes. So, I like the whole big farmer [music] space moving nicely.Good place to hide in if you're looking for lower PE. I do like Novo >> Dan >> guy. What's up with the U in your tube.>> Yeah. Not a good day. >> Not a good >> Not a good day, but it really does look like [music] it's getting a little overdone, guy.What do you think. >> I'm with you. >> Uber.>> Hurts [music] t ...

For more, let's bring in Amy Burroughs, the CEO of Turns Pharmaceuticals. Amy, great to have you with us. >> Thank you so much for having me back, Melissa.>> This was stunning for most investors, most analysts out there in terms of of the data. Three times better approximately than the standard of care right now. Can you can you sort of speak to what this means for patients and and how soon this drug can actually reach market.>> Yeah, absolutely. So chronic myo leukemia is a disease which is a chronic condi ...

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - The release of the new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory marks a significant shift in China's healthcare system towards a dual-driven model of "basic medical insurance + commercial health insurance" [1][2] Group 1: Policy Changes - The new directories will be implemented on January 1, 2026, and represent a milestone in establishing a multi-tiered medical insurance system in China [2] - The Commercial Health Insurance Innovative Drug Directory provides a high-quality "drug pool" for insurance companies, reducing the barriers for product development and information asymmetry [2][3] - The basic medical insurance directory has added 114 new drugs, achieving a negotiation success rate of 88.19%, the highest in seven years, enhancing drug coverage in critical areas [3][4] Group 2: Drug Inclusion and Coverage - The first Commercial Health Insurance Innovative Drug Directory includes 19 drugs, focusing on high-value innovative treatments that exceed basic insurance coverage, such as CAR-T therapies and Alzheimer's drugs [4][5] - Five CAR-T therapies have been included in the directory, representing over half of the currently available products in China, with prices exceeding 1 million yuan for most [5][6] - The directory also includes treatments for rare diseases, demonstrating a commitment to vulnerable populations [6] Group 3: Market Dynamics - The dual-directory system is designed to address the structural challenges of high-value innovative drugs, allowing commercial insurance to cover these costs before they are potentially included in basic insurance [7][8] - The introduction of commercial insurance funding is expected to enhance the clinical drug level and overall R&D return rates for leading innovative pharmaceutical companies [6][11] Group 4: Consumer Impact - The new payment structure allows patients to access innovative therapies without facing the dilemma of full out-of-pocket costs, as commercial insurance will provide support [8][9] - The expansion of special drug lists in commercial insurance products is becoming a trend, with many regions updating their offerings to include high-value cancer and rare disease medications [9][10] - However, challenges remain in ensuring that hospitals stock these high-cost drugs and that the claims process is efficient and transparent [10]

R&D spending has grown substantially in the 21st century as the global economy has become increasingly driven by technological innovation. Since 2008, total R&D spending across all companies in the Nasdaq Global Large Cap™ Index tripled from $342 billion to more than $1 trillion by 2023. The top quartile of R&D spenders (R&D as a % of Sales) demonstrated the fastest growth, from ~13% of aggregate revenues in 2008 to ~18% in 2024, reinvesting six times more of every dollar of revenue earned back into R&D vs. ...

DXd ADC Portfolio & Approvals - Daiichi Sankyo's DXd ADC technology received 3 World ADC Awards in 2025[21, 23, 25] - ENHERTU has achieved 15 new regulatory approvals across 15 countries/regions and 94 extension approvals across 45 countries/regions as of CY2025[31] - DATROWAY received 1 accelerated approval for TROPION-Lung05 based on Breakthrough Therapy Designation (BTD)[31] - I-DXd in SCLC and R-DXd in PROC received BTDs, totaling 13 BTDs for the DXd ADC portfolio[31] Clinical Trial Results & Advancements - DESTINY-Breast11 (Neoadjuvant) demonstrated statistically significant and clinically meaningful improvement in pCR vs ddAC-THP in patients with high-risk HER2+ eBC[39, 41] - DESTINY-Breast05 (Post Neoadjuvant) showed a 53% reduction in the risk of invasive disease recurrence or death for T-DXd compared with T-DM1 in patients with HER2+ eBC[42, 44] - In TROPION-Breast02, DATROWAY demonstrated a statistically significant and clinically meaningful improvement of ~5 months in both mOS (23.7 vs 18.7 months) and mPFS vs chemotherapy (OS HR: 0.79)[46, 48] - DATROWAY achieved an ORR of 62% vs 293% for chemotherapy in TROPION-Breast02[50] Oncology Business Performance & Strategy - Daiichi Sankyo aims to deliver 900 Billion JPY in 5 years (FY2021 to 2025)[131] - ENHERTU delivered ¥5528 Billion in revenue in FY2024, with US and EU leading the way[134] - ENHERTU has treated 194000 patients globally[132, 134] - DATROWAY global net sales exceeded 10 Billion JPY in Q2 FY'25[157] Manufacturing and Supply - Daiichi Sankyo is expanding production capacity and enhancing capabilities to maximize supply volume for 5 DXd ADCs[190, 191] - The company is utilizing both in-house manufacturing and multiple CMOs to establish diversified manufacturing and supply routes[197]